
Angela A. Armstrong
Examiner (ID: 7226, Phone: (571)272-7598 , Office: P/2659 )
| Most Active Art Unit | 2659 |
| Art Unit(s) | 2659, 2641, 2741, 2654, 2626 |
| Total Applications | 1003 |
| Issued Applications | 675 |
| Pending Applications | 123 |
| Abandoned Applications | 230 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16198622
[patent_doc_number] => 10723772
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-07-28
[patent_title] => Follistatin in treating duchenne muscular dystrophy
[patent_app_type] => utility
[patent_app_number] => 15/951929
[patent_app_country] => US
[patent_app_date] => 2018-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 20987
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15951929
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/951929 | Follistatin in treating duchenne muscular dystrophy | Apr 11, 2018 | Issued |
Array
(
[id] => 16718575
[patent_doc_number] => 20210085722
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-25
[patent_title] => DOUBLE GENE-MODIFIED STEM CELL AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/954763
[patent_app_country] => US
[patent_app_date] => 2018-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12680
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16954763
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/954763 | FGF21 and GLP1 double gene-modified mesenchymal stem cell and use in treating a metabolic disease | Apr 1, 2018 | Issued |
Array
(
[id] => 16748830
[patent_doc_number] => 20210100839
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-08
[patent_title] => NEW UNIVERSAL CHIMERIC ANTIGEN RECEPTOR T CELLS SPECIFIC FOR CD22
[patent_app_type] => utility
[patent_app_number] => 16/498276
[patent_app_country] => US
[patent_app_date] => 2018-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49834
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498276
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/498276 | Universal chimeric antigen receptor T cells specific for CD22 | Mar 29, 2018 | Issued |
Array
(
[id] => 13342857
[patent_doc_number] => 20180222968
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-09
[patent_title] => ANTIBODY THAT BINDS MURINE WISE PROTEIN
[patent_app_type] => utility
[patent_app_number] => 15/942007
[patent_app_country] => US
[patent_app_date] => 2018-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11211
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15942007
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/942007 | ANTIBODY THAT BINDS MURINE WISE PROTEIN | Mar 29, 2018 | Abandoned |
Array
(
[id] => 16012765
[patent_doc_number] => 20200181225
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => ENGINEERED T-CELL MODULATING MOLECULES AND METHODS OF USING SAME
[patent_app_type] => utility
[patent_app_number] => 16/498586
[patent_app_country] => US
[patent_app_date] => 2018-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19971
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498586
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/498586 | ENGINEERED T-CELL MODULATING MOLECULES AND METHODS OF USING SAME | Mar 27, 2018 | Abandoned |
Array
(
[id] => 17060150
[patent_doc_number] => 11104737
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-08-31
[patent_title] => ACVR2A-specific antibody and method of treatment of muscle atrophy
[patent_app_type] => utility
[patent_app_number] => 16/488082
[patent_app_country] => US
[patent_app_date] => 2018-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 65783
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16488082
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/488082 | ACVR2A-specific antibody and method of treatment of muscle atrophy | Mar 26, 2018 | Issued |
Array
(
[id] => 17922847
[patent_doc_number] => 11466080
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-11
[patent_title] => Methods of treating cancer using anti-LRP1 polyclonal antibodies
[patent_app_type] => utility
[patent_app_number] => 16/496129
[patent_app_country] => US
[patent_app_date] => 2018-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 26
[patent_no_of_words] => 13461
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16496129
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/496129 | Methods of treating cancer using anti-LRP1 polyclonal antibodies | Mar 21, 2018 | Issued |
Array
(
[id] => 17556093
[patent_doc_number] => 11312769
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-26
[patent_title] => Anti-TMEFF1 antibodies and antibody drug conjugates
[patent_app_type] => utility
[patent_app_number] => 16/495633
[patent_app_country] => US
[patent_app_date] => 2018-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 30
[patent_no_of_words] => 54714
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 217
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16495633
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/495633 | Anti-TMEFF1 antibodies and antibody drug conjugates | Mar 21, 2018 | Issued |
Array
(
[id] => 19519866
[patent_doc_number] => 12121564
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-22
[patent_title] => Use of lambda interferons in the treatment of obesity-related disorders and related diseases
[patent_app_type] => utility
[patent_app_number] => 16/604378
[patent_app_country] => US
[patent_app_date] => 2018-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 19
[patent_no_of_words] => 21052
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604378
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/604378 | Use of lambda interferons in the treatment of obesity-related disorders and related diseases | Mar 15, 2018 | Issued |
Array
(
[id] => 15646701
[patent_doc_number] => 20200085880
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-19
[patent_title] => METHODS AND COMPOSITIONS FOR ENHANCING CARDIOMYOCYTE MATURATION AND ENGRAFTMENT
[patent_app_type] => utility
[patent_app_number] => 16/493888
[patent_app_country] => US
[patent_app_date] => 2018-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29961
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16493888
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/493888 | Methods and compositions for enhancing cardiomyocyte maturation and engraftment | Mar 14, 2018 | Issued |
Array
(
[id] => 17377040
[patent_doc_number] => 11235029
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-02-01
[patent_title] => Methods for treating heart failure with a TRKB agonist
[patent_app_type] => utility
[patent_app_number] => 15/916494
[patent_app_country] => US
[patent_app_date] => 2018-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 15
[patent_no_of_words] => 27030
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 176
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15916494
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/916494 | Methods for treating heart failure with a TRKB agonist | Mar 8, 2018 | Issued |
Array
(
[id] => 13413287
[patent_doc_number] => 20180258186
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-09-13
[patent_title] => NME Inhibitors and Methods of Using NME Inhibitors
[patent_app_type] => utility
[patent_app_number] => 15/910894
[patent_app_country] => US
[patent_app_date] => 2018-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28480
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15910894
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/910894 | NME Inhibitors and Methods of Using NME Inhibitors | Mar 1, 2018 | Abandoned |
Array
(
[id] => 17497608
[patent_doc_number] => 11286301
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-29
[patent_title] => Antifibrotic activity of CD47 blockade
[patent_app_type] => utility
[patent_app_number] => 16/487051
[patent_app_country] => US
[patent_app_date] => 2018-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 49
[patent_figures_cnt] => 75
[patent_no_of_words] => 21412
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16487051
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/487051 | Antifibrotic activity of CD47 blockade | Feb 27, 2018 | Issued |
Array
(
[id] => 17089787
[patent_doc_number] => 11117964
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-14
[patent_title] => Anti-KIR3DL1 antibodies
[patent_app_type] => utility
[patent_app_number] => 16/484451
[patent_app_country] => US
[patent_app_date] => 2018-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 26333
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 403
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16484451
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/484451 | Anti-KIR3DL1 antibodies | Feb 25, 2018 | Issued |
Array
(
[id] => 17921636
[patent_doc_number] => 11464857
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-11
[patent_title] => Low-viscosity, high concentration evolocumab formulations and methods of making the same
[patent_app_type] => utility
[patent_app_number] => 15/902775
[patent_app_country] => US
[patent_app_date] => 2018-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 36
[patent_figures_cnt] => 75
[patent_no_of_words] => 43391
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 200
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15902775
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/902775 | Low-viscosity, high concentration evolocumab formulations and methods of making the same | Feb 21, 2018 | Issued |
Array
(
[id] => 13524567
[patent_doc_number] => 20180313826
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-01
[patent_title] => BIOMARKER FOR CORONARY ARTERY DISEASE
[patent_app_type] => utility
[patent_app_number] => 15/900680
[patent_app_country] => US
[patent_app_date] => 2018-02-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21075
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15900680
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/900680 | Circulating antibodies against MAA adducts as biomarker for coronary artery disease | Feb 19, 2018 | Issued |
Array
(
[id] => 16009335
[patent_doc_number] => 20200179510
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5 INHIBITION SUPPRESSES TUMOR FORMATION
[patent_app_type] => utility
[patent_app_number] => 16/496252
[patent_app_country] => US
[patent_app_date] => 2018-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27168
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16496252
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/496252 | LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5 INHIBITION SUPPRESSES TUMOR FORMATION | Feb 15, 2018 | Abandoned |
Array
(
[id] => 12842494
[patent_doc_number] => 20180172671
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-06-21
[patent_title] => METHODS FOR TREATING NEURAL CELL SWELLING
[patent_app_type] => utility
[patent_app_number] => 15/895945
[patent_app_country] => US
[patent_app_date] => 2018-02-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21550
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15895945
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/895945 | METHODS FOR TREATING NEURAL CELL SWELLING | Feb 12, 2018 | Abandoned |
Array
(
[id] => 15649689
[patent_doc_number] => 20200087374
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-19
[patent_title] => INTERACTION BETWEEN C-PEPTIDES AND ELASTIN RECEPTOR, A MODEL FOR UNDERSTANDING VASCULAR DISEASE
[patent_app_type] => utility
[patent_app_number] => 16/483717
[patent_app_country] => US
[patent_app_date] => 2018-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50296
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16483717
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/483717 | INTERACTION BETWEEN C-PEPTIDES AND ELASTIN RECEPTOR, A MODEL FOR UNDERSTANDING VASCULAR DISEASE | Feb 4, 2018 | Abandoned |
Array
(
[id] => 15649675
[patent_doc_number] => 20200087367
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-19
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE
[patent_app_type] => utility
[patent_app_number] => 16/482883
[patent_app_country] => US
[patent_app_date] => 2018-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 68098
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -123
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16482883
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/482883 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | Feb 4, 2018 | Abandoned |